Seres Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
MCRB$1.70-14.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed/ | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | File No. | Exhibit | FilingDate | FurnishedHerewith |
| 3.1 | Restated Certificate of Incorporation, filed on July 1, 2015 | 8-K | 001-37465 | 3.1 | 7/1/15 | |
| 3.2 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated June 27, 2023 | 8-K | 001-37465 | 3.1 | 6/28/23 | |
| 3.3 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 2024 | 8-K | 001-37465 | 3.1 | 4/8/24 | |
| 3.4 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 21, 2025 | 8-K | 001-37465 | 3.1 | 4/22/25 | |
| 3.5 | Amended and Restated Bylaws | 8-K | 001-37465 | 3.1 | 1/2/24 | |
| 10.1 | Third Amendment to Lease and Termination Agreement, dated July 31, 2026, by and between Seres Therapeutics, Inc. and BMR-Sidney Research Campus, LLC | 8-K | 001-37465 | 10.1 | 8/4/26 | |
| 10.2 | Stock Issuance Agreement, dated July 31, 2026, by and between Seres Therapeutics, Inc. and BMR-Sidney Research Campus, LLC | 8-K | 001-37465 | 10.2 | 8/4/26 | |
| 10.3 | Advisory Agreement, dated November 2, 2026, by and between Marella Thorell and Seres Therapeutics, Inc. | |||||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Interim Chief Executive Officer | * | ||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | * | ||||
| 32.1 | Section 1350 Certification of Interim Chief Executive Officer | ** | ||||
| 32.2 | Section 1350 Certification of Chief Financial Officer | ** | ||||
| 101.INS | Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.